secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001437749-24-035806
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals appoints Michael Abrams as permanent CFO, base salary $325,000
--------------------------------------------------------------------------------

- Michael Abrams appointed CFO effective Nov 18, 2024, succeeding interim CFO Richard Narido.
- Base salary $325,000; initially 50% until Qualified Financing or Feb 1, 2025.
- Granted 50,000 stock options under 2021 Omnibus Incentive Plan, vesting over three years.
- Abrams previously CFO at Arch Therapeutics, RiseIT Solutions, and FitLife Brands.
- Employment agreement includes non-compete, non-solicitation, and severance provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/0001437749-24-035806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/nrxp20241120_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-035806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer